TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01201057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.0% SPL7013 Gel
Description: Vaginal gel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Vaginal gel
Study: NCT02398903

Intervention type: OTHER
Intervention: Blood samples for measurement of drug Css
Description: Blood samples for measurement of drug Css
Study: NCT02521402

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biovance
Description: decellularized, dehydrated human amniotic membrane
Study: NCT03505281

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Patients:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml blood (EDTA)~* 2 tubes of 7 ml blood (EDTA) for 20 NET Covid patients~Healthy volunteers:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml of blood (EDTA)~* 1 tube of 4 ml (citrate)

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Patients:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml blood (EDTA)~* 2 tubes of 7 ml blood (EDTA) for 20 NET Covid patients~Healthy volunteers:~* 1 tube of 4 ml blood (Lithium Heparinate)~* 3 tubes of 7 ml of blood (EDTA)~* 1 tube of 4 ml (citrate)
Study: NCT03464487

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic Index Therapy Diet
Description: Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Glycemic Index Therapy Diet
Description: Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.
Study: NCT03051503

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The Transdermal Therapeutic System-Fentanyl (TTS-F)
Description: (TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) morphine
Description: IV PCA morphine for pain in the postoperative period.
Study: NCT01741519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDLL600
Description: Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brevibloc
Description: Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
Study: NCT01836705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503 (TG101348)
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panolosetron
Description: Pharmaceutical form:solution~Route of administration: intravenous
Study: NCT01648348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Endoglin Chimeric Monoclonal Antibody TRC105
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02398903

Intervention type: OTHER
Intervention: DXA and impedancemetry
Description: Body composition by DXA and impedancemetry

Intervention type: OTHER
Intervention: DXA and impedancemetry
Description: Body composition by DXA and impedancemetry
Study: NCT01648348

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02532556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Digitimer)
Description: Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Digitimer)
Description: Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Digitimer)
Description: Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Digitimer)
Description: Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Digitimer)
Description: Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Digitimer)
Description: Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Digitimer)
Description: Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
Study: NCT06022835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate-gel (CHG) Dressing
Description: Participants used Tegaderm™ CHG dressing for 4 months. The dressing was changed every seven days or soiled.
Study: NCT02674217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation
Description: autologous transplant using non-frozen peripheral blood stem cells
Study: NCT02925273

Intervention type: OTHER
Group type: OTHER
Intervention: palmar grasp without dorsal stimulation
Description: The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~1. Flexion at the distal interphalangeal joint of the hand~2. Flexion at the proximal interphalangeal joint of the hand~3. Flexion at the metacarpal-phalangeal joint of the hand

Intervention type: OTHER
Group type: OTHER
Intervention: standard palmar grasp test with dorsal stimulation
Description: The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
Study: NCT05120011

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine-L-tartrate
Study: NCT01669798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: PO 200mg BID
Study: NCT03390868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based training for staff
Description: This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Web-based training for staff
Description: This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
Study: NCT01177423

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental anesthesia
Description: Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
Study: NCT05120011

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-leucine
Description: L-leucine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-leucine
Description: L-leucine
Study: NCT04109911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented oyster extract
Description: Fermented oyster extract 1,200 mg/day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03636321

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: living donor liver transplantation with internal biliary stent
Description: living donor liver transplantation without internal biliary stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: living donor liver transplantation with internal biliary stent
Description: living donor liver transplantation without internal biliary stent
Study: NCT02354586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Study: NCT00003520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02490423

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nudges Intervention
Description: The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
Study: NCT02444312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benefit-finding Writing Activity
Description: Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Writing Activity
Description: The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
Study: NCT04840407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHARP coach intervention
Description: The Coach provides guidance and support through four 45-60 minute in-home visits: Visit 1: to facilitate effective team communication, this visit is conducted, when possible, with the rehabilitation therapist, the patient/family, the direct care aide and the Coach, who jointly reviews the rehabilitation plan of care. Visits 2-4 include: discussion/observation of HHA/patient exercise repetition sessions, along with: 1) discussing falls prevention, signs of a recurrent stroke and when to call 911; 2) modeling motivation techniques, assessing adherence barriers and revising strategies for addressing them; and 3) identifying/ reporting signs of anxiety/depression. Additional coaching visits and calls may be scheduled as needed depending on the aide's progress in addressing barriers and the patient's progress toward rehabilitation goals.
Study: NCT02578732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXA
Description: Schema:~1 cycle = 14 days \*\*It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG\*\*~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~* It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~* Antiemetics will be administered as per standard institutional policy.
Study: NCT01499914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccination
Description: Influenza vaccination in patients with cystic fibrosis
Study: NCT02398903

Intervention type: OTHER
Intervention: DXA and impedancemetry
Description: Body composition by DXA and impedancemetry
Study: NCT04226911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S&SEs
Description: S\&SEs:~As many sugar-containing products in the diet as possible should be replaced with S\&SE-containing products.~To ensure that a certain amount of S\&SE products is consumed every day, a fixed minimum amount of units for each individual is planned.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sugar
Description: Sugar group:~In the sugar group it is allowed to consume up to a certain number of units of sugar-containing products each day, corresponding to \< 10 E% added sugar.~The sugar group is not allowed to consume any S\&SE products.
Study: NCT02989766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education on Breast Feeding
Description: Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
Study: NCT04128254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban Oral Tablet
Description: Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apixaban Oral Tablet
Description: Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
Study: NCT00625807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RR
Description: A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MBSR
Description: A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
Study: NCT02125188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin 3ug/kg ivdrip before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline 100ml ivdrip before surgery
Study: NCT01614509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravitreal bevacizumab monotherapy
Description: The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection
Description: The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
Study: NCT01584986

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACP injections
Description: Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
Study: NCT02993250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
Study: NCT03820193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodon/Acetaminophen
Description: Traditionally used narcotic pain control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Post-Operative Non Opioid Pain Protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Post-Operative Non Opioid Pain Protocol
Study: NCT00876278

Intervention type: DEVICE
Group type: OTHER
Intervention: *AT.Smart 46LC
Description: Primary implantation of \*AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the \*AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
Study: NCT02708277

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: loop-shaped intrauterine contraceptive device
Description: Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrauterine balloon (Cook Medical)
Description: The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
Study: NCT03057587

Intervention type: DEVICE
Intervention: NIRS Monitoring
Description: NIRS data will be collected throughout the surgery
Study: NCT01482624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronan (0.5%, 5 mg/10 ml)
Description: Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard arthroscopic meniscal surgery
Description: Standard arthroscopic meniscal surgery without add-on treatment.
Study: NCT04602104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low dose hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (2.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dose hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (8.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (16.0\*10\^8 particles at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dosage 1of hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (a quarter of MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dosage 2 of hMSC-Exos
Description: basic treatment and 7 times aerosol inhalation of hMSC-Exos (MTD/day at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: No hMSC-derived exosomes
Description: basic treatment and 7 times aerosol inhalation of normal saline (at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
Study: NCT01193621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol, PET
Description: 1. Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~2. D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days.
Study: NCT01938651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high field strength magnetic resonance imaging
Description: Undergo 7T MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance spectroscopic imaging
Description: Undergo 31P MRS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemical exchange saturation transfer magnetic resonance imaging
Description: Undergo CEST-MRI